HealthPolitics

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 14:51:24 UTC.

Briefings

Beam Therapeutics announced its CRISPR-based treatment for sickle cell disease, risto-cel, achieved the primary goal of a pivotal clinical trial by providing freedom from severe pain crises for at least 12 months. The company plans to file an FDA marketing application for the therapy as soon as the end of 2026. PepGen also reported promising early data for a drug targeting muscular dystrophy, though specific metrics were not detailed in the provided text.

Key points

• Beam Therapeutics achieved the primary goal of a pivotal clinical trial for its CRISPR-based treatment risto-cel in sickle cell disease, offering freedom from severe pain crises for at least 12 months.
• Beam Therapeutics plans to file an FDA marketing application for risto-cel as soon as the end of 2026.

Context

This finding represents a significant milestone in the development of gene therapy for sickle cell disease, with Beam Therapeutics aiming to move from trial completion to regulatory approval within the next year.

Limitations

The provided evidence is limited to two biotech company announcements regarding clinical trial outcomes and future filings. Specific detailed data, patient numbers, and statistical results for both treatments are not disclosed in the source text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 10/11/2026, 14:57:05 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeibs4eooeolygt6jxmgnbfv7dtthz2bjjf4mf2bphabnn7knzh3ty4